Pregnancy, Childbirth & Puerperium

Group B Streptococcus screening and intrapartum prophylaxis

Clinical Overview and When to Suspect GBS Colonization

— Without prophylaxis, ~1–2% of colonized mothers transmit invasive disease to the neonate; with intrapartum antibiotic prophylaxis (IAP), vertical transmission drops by ~80%.

— Every pregnancy ≥ 36 0/7 weeks → universal screening (ACOG 2019, CDC).

— GBS bacteriuria at any colony count during the current pregnancy → treat acutely if symptomatic or ≥10⁵ CFU/mL, AND give IAP regardless of culture later.

— Prior infant with invasive GBS disease → automatic IAP in subsequent pregnancies.

— Unknown GBS status with risk factors at delivery (preterm <37 wk, ROM ≥18 h, intrapartum fever ≥100.4°F/38°C).

Group B Streptococcus (Streptococcus agalactiae) is a gram-positive, β-hemolytic encapsulated coccus that colonizes the gastrointestinal and genitourinary tracts of 10–30% of pregnant individuals in the United States.

Colonization is typically asymptomatic in the mother but is the leading cause of early-onset neonatal sepsis (EOGBS) — presenting in the first 7 days of life as bacteremia, pneumonia, or meningitis.

When to "suspect" or act on GBS in obstetric practice:

Board pearl: GBS in urine (any quantity) during pregnancy is a marker of heavy genital tract colonization — patient gets IAP at delivery and you do not need to repeat the rectovaginal swab at 36 weeks.

Step 3 management: Document GBS status, gestational age, allergy history (and severity), and prior obstetric GBS history on every prenatal record by the third trimester — these four data points drive every intrapartum antibiotic decision.

Distinguish from late-onset GBS disease (7–89 days), which is not prevented by intrapartum prophylaxis and is acquired horizontally — counseling families about this matters at discharge.

Step 3 favors longitudinal logic: screening at 36–37 wk, plan documented, antibiotics started promptly in labor, neonate observed per AAP algorithm.

Presentation Patterns and Key History

— Routine 36–37 week prenatal visit in an asymptomatic patient → time to screen.

— Term or preterm labor in a patient whose GBS status is positive, unknown, or negative >5 weeks old.

— Preterm prelabor rupture of membranes (PPROM) — start GBS prophylaxis empirically while latency antibiotics run.

— Postpartum maternal infection (endometritis, bacteremia, chorioamnionitis) or neonatal early-onset sepsis triggering a look-back.

— Gestational age (drives screening vs empiric IAP).

— Prior pregnancies: any infant with invasive GBS disease? Any prior GBS-positive pregnancy (does not mandate IAP this pregnancy — re-screen).

— Current pregnancy: any GBS bacteriuria, even asymptomatic?

— Membrane status and duration of rupture.

— Intrapartum temperature (≥100.4°F suggests intraamniotic infection — change antibiotics).

— Penicillin allergy: rash vs anaphylaxis/angioedema/SJS — this changes the regimen entirely.

GBS colonization itself is clinically silent in pregnancy — the "presentation" you encounter on Step 3 is usually one of four scenarios:

Key history elements to extract on the vignette:

Key distinction: A prior pregnancy with GBS colonization does NOT itself require IAP in the current pregnancy — only a prior neonate with invasive GBS disease does. Step 3 loves this trap.

Board pearl: GBS-positive screen >5 weeks before delivery is considered expired — if labor begins after that window, retest is impractical, so manage as unknown status.

Re-screen at admission if symptoms of UTI emerge or labor presents preterm and prior cultures are absent.

Document allergy reaction phenotype in the chart at the screening visit so labor-and-delivery does not have to guess at 3 a.m.; this is a classic Step 3 transitions-of-care vulnerability.

Physical Exam Findings and Intrapartum Assessment

— Vital signs: maternal T ≥100.4°F (38°C), maternal tachycardia >100, fetal tachycardia >160 — together suggest intraamniotic infection (chorioamnionitis/Triple I).

— Fundal tenderness and purulent or foul amniotic fluid support intraamniotic infection.

— Speculum/sterile vaginal exam: confirm ROM (pooling, ferning, nitrazine), assess cervical dilation, station — these define "in labor" for IAP timing.

— Fetal heart tracing: Category II/III changes can be early signs of fetal infection.

— Maternal GBS bacteremia or sepsis → hypotension, tachycardia, lactate elevation → activate sepsis bundle (fluids, broad antibiotics, source control).

— Postpartum endometritis: fever >24 h postpartum, uterine tenderness, foul lochia.

— Grunting, tachypnea, temperature instability, poor perfusion within 24 h of birth.

— These trigger the AAP neonatal early-onset sepsis (EOS) risk calculator pathway.

Maternal exam in isolated GBS colonization is normal — no discharge, no tenderness, no fever. The exam pivots when colonization intersects labor, ROM, or infection.

Focused intrapartum exam at admission:

Hemodynamic assessment matters when GBS escalates:

Neonatal exam clues that retrospectively suggest GBS exposure:

CCS pearl: In a CCS-style labor case, order maternal vitals q4h in latent labor, q1h in active labor, continuous fetal monitoring once IAP is running, and check temperature more frequently if ROM is prolonged. Document the time of first antibiotic dose — adequacy of prophylaxis hinges on ≥4 hours before delivery.

Board pearl: If the patient meets criteria for intraamniotic infection, you stop calling it "GBS prophylaxis" — she now needs broad-spectrum treatment (ampicillin + gentamicin, add clindamycin or metronidazole after cesarean), which also covers GBS.

Diagnostic Workup — Screening Culture and Initial Labs

— Swab the lower vagina first, then the rectum (through the anal sphincter) with the same swab — do NOT use a speculum.

— Patient self-collection is acceptable and equally sensitive when instructed.

— Transport in non-nutritive medium → laboratory inoculates selective enrichment broth (Lim or Trans-Vag) → subculture to blood agar. Enrichment is mandatory; direct plating misses ~50%.

— Can be performed on enriched broth (higher sensitivity) or directly intrapartum on a vaginal-rectal swab when status is unknown.

— Intrapartum NAAT is an option but not a substitute for antenatal screening — culture also provides antibiotic susceptibilities, which matter for penicillin-allergic patients.

— Urine culture at the first prenatal visit — if GBS grows at any colony count, treat symptomatic UTI/pyelonephritis and flag for IAP.

— If chorioamnionitis suspected: CBC, blood culture, consider amniocentesis for Gram stain/culture/glucose in select cases.

Universal screening: rectovaginal swab at 36 0/7 to 37 6/7 weeks gestation (updated from 35–37 in 2019 by ACOG/CDC to extend coverage window since results remain valid for 5 weeks).

Specimen technique (high-yield):

Results take 24–72 hours. Document positive, negative, or NAAT result in the prenatal chart.

NAAT (PCR) for GBS:

Other relevant labs depending on scenario:

Key distinction: GBS urine culture ≥10⁵ CFU/mL in pregnancy → treat as asymptomatic bacteriuria now (penicillin or amoxicillin) AND give IAP at delivery. Lower counts → no treatment now, but still IAP at delivery.

Board pearl: A negative GBS screen done >5 weeks before delivery is considered unknown — re-test if time allows, otherwise manage by risk factors. Step 3 will date the screen specifically; check the timeline.

Always request antibiotic susceptibility (clindamycin and erythromycin) on positive cultures from penicillin-allergic patients — drives the choice of cefazolin vs clindamycin vs vancomycin.

Diagnostic Workup — Susceptibility, NAAT, and Special Situations

— Order GBS culture with sensitivities to clindamycin and erythromycin and, when available, D-test for inducible clindamycin resistance.

— Up to 20–40% of GBS isolates are clindamycin-resistant in the US; erythromycin resistance is even higher and predicts clindamycin failure when D-test is positive.

— Low-risk allergy (isolated rash, family history, GI upset, unknown reaction in childhood) → cefazolin is safe; cross-reactivity with 1st-gen cephalosporins is <1–2%.

— High-risk allergy (anaphylaxis, angioedema, respiratory distress, urticaria, hypotension, SJS/TEN, DRESS) → avoid β-lactams; use clindamycin if susceptible, vancomycin if resistant/unknown.

— Penicillin allergy testing during pregnancy is increasingly recommended antenatally to de-label patients and enable β-lactam use — safe in 2nd/3rd trimester.

— Unknown GBS status presenting in labor at term, time permitting.

— Cannot determine susceptibility — assume resistance and use vancomycin for high-risk allergic patients when NAAT is positive intrapartum.

— Planned cesarean delivery before labor and with intact membranes → no IAP needed regardless of GBS status because vertical transmission risk is negligible. Still screen, in case labor starts unexpectedly.

— PPROM → admit, send GBS culture if unknown, start ampicillin (covers GBS) + azithromycin + amoxicillin per latency protocol.

— Threatened preterm labor that resolves → if GBS culture was sent and is negative, valid for 5 weeks; if positive, treat at delivery.

When the prenatal record lists penicillin allergy, the lab workflow changes:

Penicillin allergy clarification — a Step 3 favorite:

Intrapartum NAAT indications:

Special scenarios:

Step 3 management: Always re-check the chart for: (1) GBS screen date and result, (2) susceptibility panel if allergic, (3) prior infant with invasive GBS disease — these three items dictate the antibiotic order in nearly every case.

Board pearl: D-test positive = inducible clindamycin resistance = do not use clindamycin; switch to vancomycin.

Risk Stratification and the IAP Decision Algorithm

— Positive GBS rectovaginal screen in the current pregnancy (≤5 weeks old).

— GBS bacteriuria at any colony count in the current pregnancy.

— Previous infant with invasive GBS disease.

— Unknown GBS status PLUS any of: delivery <37 0/7 weeks, ROM ≥18 hours, intrapartum T ≥100.4°F (38°C), or intrapartum NAAT positive.

— Positive GBS in a prior pregnancy (without invasive neonatal disease).

— Negative GBS screen within 5 weeks, even with risk factors.

— Planned cesarean before labor with intact membranes (regardless of GBS status).

— "Adequate IAP" = ≥4 hours of penicillin, ampicillin, or cefazolin before delivery. This threshold drives neonatal management.

— Clindamycin and vancomycin do not currently count toward the "adequate" 4-hour window for neonatal risk stratification — the neonate is treated as inadequately prophylaxed even if mom got the drug on time.

— Start IAP immediately when labor is suspected or membranes rupture; if labor arrests and GBS screen returns negative, discontinue.

— If positive and labor restarts later, give IAP again at that admission.

Indications for intrapartum antibiotic prophylaxis (IAP):

NOT indications for IAP:

Timing matters more than agent choice:

Risk stratification in preterm labor / PPROM:

Key distinction: A scheduled cesarean in labor or with ROM still requires IAP if GBS-positive — only scheduled cesarean with intact membranes and no labor is exempt.

CCS pearl: When you "admit to L&D," include orders for: GBS status review, IAP if indicated (with first dose stat), allergy verification, continuous fetal monitoring, and notify pediatrics if any risk factor is present.

Board pearl: The neonatal sepsis risk calculator weighs highest maternal intrapartum temperature, GBS status, ROM duration, gestational age, and IAP adequacy — knowing which IAP "counts" matters at the bedside.

Pharmacotherapy — First-Line IAP Regimens

— 5 million units IV loading dose, then 2.5–3 million units IV every 4 hours until delivery.

— Narrow spectrum minimizes selection pressure and neonatal microbiome disruption.

— 2 g IV load, then 1 g IV every 4 hours.

— Used when ampicillin is already running (PPROM latency, chorioamnionitis treatment).

— Cefazolin 2 g IV load, then 1 g IV every 8 hours until delivery.

— Counts as "adequate IAP" if ≥4 hours before delivery.

— Clindamycin 900 mg IV every 8 hours.

— Does NOT count as adequate IAP for neonatal risk-calculator purposes.

— Vancomycin 20 mg/kg IV every 8 hours (max 2 g per dose) — weight-based dosing replaced the old flat 1 g dose in 2019.

— Also does NOT count as adequate IAP for neonatal classification.

First-line agent: Penicillin G

Acceptable alternative: Ampicillin

Penicillin allergy — low risk (no anaphylaxis, no angioedema, no SJS):

Penicillin allergy — high risk, GBS isolate susceptible to clindamycin (and D-test negative):

Penicillin allergy — high risk, GBS resistant or susceptibility unknown:

Erythromycin is no longer recommended for GBS prophylaxis (high resistance, poor placental transfer).

Continue IAP every 4 hours until delivery — do not stop after a single "loading" dose.

Board pearl: Memorize the ladder: Penicillin G → Cefazolin (low-risk allergy) → Clindamycin (if susceptible + D-test negative) → Vancomycin (high-risk allergy with resistance/unknown).

Step 3 management: When ordering IAP in CCS, specify the drug, dose, route, frequency, and start time — the grader is looking for the q4h dosing pattern and stat first dose. Do not order PO antibiotics; IAP is IV only.

Adverse effects to anticipate: penicillin/ampicillin → maternal anaphylaxis (rare, monitor first 30 min); vancomycin → infusion-related "red man" reaction → slow the infusion, don't switch drugs.

Procedural and Adjunctive Management Considerations

— IV access secured on admission to L&D for any GBS-indicated patient.

— First dose stat — do not wait for "active" labor if criteria are met (e.g., ROM ≥18 h or preterm).

— Re-dose q4h penicillin/ampicillin, q8h cefazolin/clindamycin/vancomycin through delivery, including during prolonged second stage.

— Standard pre-incision cefazolin 2 g IV (3 g if >120 kg) for surgical site infection prophylaxis covers GBS — no additional IAP needed.

— Add azithromycin 500 mg IV for unscheduled (intrapartum) cesarean to reduce endometritis.

— If patient was already mid-IAP for GBS, that satisfies surgical prophylaxis as well; document timing.

— Membrane sweeping is not contraindicated in GBS-positive patients.

— Internal monitors (fetal scalp electrode, intrauterine pressure catheter) are not contraindicated but should follow standard indications.

— Avoid routine artificial ROM to prolong labor solely for progress in GBS-positive patients — extends exposure window.

— If the patient developed chorioamnionitis, continue broad-spectrum antibiotics (ampicillin + gentamicin ± clindamycin/metronidazole) for at least one afebrile dose postpartum (or per institutional protocol).

— Uncomplicated IAP needs no postpartum antibiotic continuation.

— Communicate IAP status, drug, doses, and timing of last dose relative to delivery at every birth.

— Inadequate IAP + risk factors → AAP algorithm may require neonatal observation, CBC/blood culture, or empiric antibiotics.

IAP is fundamentally a timing-and-route intervention — operational details determine effectiveness:

Cesarean delivery considerations:

Labor procedures and GBS:

Postpartum:

Neonatal management hand-off:

CCS pearl: After delivery, order routine postpartum care; the IAP order should auto-discontinue. Do not continue IV antibiotics unless infection is suspected — Step 3 dings unnecessary antibiotics.

Board pearl: Pre-incision cefazolin for cesarean covers GBS; you do not need to "double up." Watch for question stems trying to make you give two β-lactams.

Special Populations — Renal Impairment and Drug-Specific Adjustments

— Renally cleared. In CrCl <10 mL/min or dialysis, extend interval to q8h. Most pregnant patients have preserved or augmented clearance — standard dosing is fine.

— In severe hepatic dysfunction alone, no adjustment needed.

— Adjust for CrCl <55 mL/min: 1 g q8h becomes q12h; <35 mL/min → q12–24h.

— Obese patients (>120 kg) → 3 g pre-cesarean for surgical prophylaxis.

— Predominantly hepatic metabolism — no adjustment in renal impairment, modest reduction in severe hepatic disease.

— Watch for C. difficile risk even after brief exposure — counsel on postpartum diarrhea.

— Weight-based 20 mg/kg IV q8h, max 2 g/dose. In renal impairment, extend interval; ideally monitor levels for prolonged courses, but single intrapartum dosing rarely requires troughs.

— Infusion rate ≤1 g/hour to prevent flushing/hypotension; if reaction occurs, slow the infusion, give antihistamine, do not relabel as allergy.

— β-lactams largely safe; clindamycin requires caution; vancomycin unchanged.

Pregnancy normally produces hyperdynamic renal function (GFR ↑ 50%), but Step 3 vignettes layer on chronic kidney disease, preeclampsia with AKI, or sepsis-induced AKI that affect dosing.

Penicillin G:

Ampicillin: similar to penicillin G — renal dose adjustment for CrCl <30 mL/min (q6–12h). Beware rash with concurrent viral illness (mononucleosis-like) — non-allergic phenomenon.

Cefazolin:

Clindamycin:

Vancomycin:

Hepatic impairment:

Step 3 management: In a pregnant patient with preeclampsia and rising creatinine, you do not delay GBS prophylaxis — you adjust intervals. The risk of EOGBS dwarfs the modest risk of extended-interval β-lactam.

Board pearl: Augmented renal clearance in healthy pregnancy means standard penicillin dosing achieves adequate fetal/amniotic levels rapidly — that's why the 4-hour threshold works.

Special Populations — Preterm Labor, PPROM, Adolescents, and Recurrent Pregnancy

— Begin IAP empirically at admission; send a rectovaginal culture if not done.

— If labor arrests and culture returns negative within 5 weeks, no IAP needed if labor recurs within that window.

— If positive, IAP at every subsequent labor admission in this pregnancy.

— Latency antibiotic regimen: ampicillin 2 g IV q6h + azithromycin 1 g PO once, then amoxicillin 500 mg PO q8h + extended PO regimen for 7 days.

— Ampicillin covers GBS during the 48-hour IV phase; once labor begins, switch to standard IAP if GBS-positive or unknown.

— Same screening and prophylaxis algorithm; ensure confidential counseling about future pregnancies and that GBS positivity does not mean a sexually transmitted infection — common misconception to address.

— Offer concurrent STI screening per routine prenatal care.

— Prior GBS-positive screen in a previous pregnancy does NOT mandate IAP in the next — re-screen at 36–37 weeks.

— Prior infant with invasive GBS disease does mandate automatic IAP in every subsequent pregnancy without re-screening.

Preterm labor (<37 weeks) with unknown GBS status:

Preterm prelabor rupture of membranes (PPROM, <34 weeks):

Adolescent pregnancies:

Recurrent pregnancies:

Multifetal gestation: same screening protocol; deliver per obstetric indication. IAP continues until delivery of the last fetus.

Home birth / birthing center transfers: confirm GBS status on transfer; if unknown and risk factors present, start IAP on arrival.

HIV-positive pregnant patients: standard GBS protocol applies — no modification of screening or IAP, but coordinate with ART regimen for interactions (minimal with β-lactams).

Key distinction: Two automatic-IAP triggers bypass screening — GBS bacteriuria this pregnancy and prior infant with invasive GBS — memorize both.

Board pearl: PPROM patients on latency ampicillin are effectively receiving GBS coverage; if labor begins within that window and they are GBS-positive, continue ampicillin q4h dosing through delivery rather than switching agents.

Complications and Adverse Outcomes

— Early-onset GBS disease (0–6 days): bacteremia (80%), pneumonia (10%), meningitis (7%). Mortality 2–3% term, 20–30% preterm. Long-term neurodevelopmental sequelae in meningitis survivors (~30%).

— Late-onset disease (7–89 days): not prevented by IAP; often meningitis with worse outcomes. Counsel families to seek care for fever, poor feeding, lethargy.

— Stillbirth: GBS chorioamnionitis is an underrecognized cause; intrauterine infection can precede labor.

— Chorioamnionitis / intraamniotic infection → treat with broad-spectrum antibiotics, expedite delivery (do not perform cesarean solely for infection unless other indications).

— Postpartum endometritis — fever, uterine tenderness, foul lochia within 24–72 h postpartum.

— GBS bacteremia / urosepsis during pregnancy or postpartum.

— Wound infection after cesarean delivery.

— Rare: GBS meningitis, endocarditis, necrotizing fasciitis in immunocompromised mothers.

— Maternal anaphylaxis (penicillin) — 4 per 10,000 doses, fatal in 1 per 100,000. Justifies thorough allergy history.

— Vancomycin infusion reaction — flushing, hypotension; manage by slowing rate.

— C. difficile colitis (especially clindamycin).

— Neonatal microbiome alteration — emerging concern; mitigated by narrow-spectrum penicillin.

— Even adequate IAP reduces EOGBS by ~80%, not 100%. Cases still occur — always evaluate ill neonates seriously regardless of maternal IAP.

Neonatal complications (the main reason IAP exists):

Maternal complications:

Antibiotic-related complications:

Failure of prophylaxis:

Board pearl: A neonate of an adequately treated GBS-positive mother who appears ill is not "covered" — sepsis evaluation proceeds per AAP algorithm.

Step 3 management: Postpartum fever >24 hours with uterine tenderness → endometritis → IV clindamycin + gentamicin (gold standard) until afebrile 24–48 h; no oral step-down needed for uncomplicated endometritis.

When to Escalate Care — Sepsis, ICU, and Consultation

— Suspected maternal sepsis: qSOFA ≥2 (SBP ≤100, RR ≥22, altered mental status), lactate >2, or hypotension unresponsive to 30 mL/kg crystalloid → ICU transfer, MFM and critical care consult.

— Refractory chorioamnionitis despite broad-spectrum antibiotics → consider source control (expedite delivery), evaluate for abscess.

— Anaphylaxis to IAP: IM epinephrine 0.3–0.5 mg, IV fluids, airway, antihistamines, steroids; transfer to monitored bed.

— Necrotizing soft tissue infection / postpartum toxic shock: surgical consult immediately.

— Any neonate with respiratory distress, temperature instability, hypotonia, poor perfusion, or seizures → NICU, full sepsis workup (CBC, blood culture, LP, empiric ampicillin + gentamicin).

— Inadequate IAP + maternal chorioamnionitis → at minimum, neonatal observation 36–48 hours with vitals q4h; many centers do CBC and blood culture per AAP EOS calculator.

— Maternal-Fetal Medicine for PPROM <34 weeks, recurrent loss with GBS, complex penicillin allergy.

— Allergy/Immunology antenatally for penicillin de-labeling — increasingly standard.

— Infectious Disease for invasive maternal GBS, recurrent UTI, suspected resistant organism.

— Neonatology at delivery whenever IAP is inadequate or chorioamnionitis is diagnosed.

Escalate maternal care when:

Escalate neonatal care when:

Consultations:

CCS pearl: In a CCS case where maternal vitals deteriorate intrapartum (T 39, HR 130, BP 85/50, tracing non-reassuring), order: blood cultures, CBC, lactate, broaden antibiotics to ampicillin + gentamicin (+ clindamycin if cesarean), IV fluids, notify anesthesia and neonatology, and expedite delivery. Do not delay broadening to wait for cultures.

Board pearl: Triple I (intrauterine inflammation or infection or both) is the current ACOG term replacing chorioamnionitis; diagnostic criteria include maternal fever (≥39°C single, or 38–38.9°C sustained) plus one of: fetal tachycardia, maternal WBC >15,000, or purulent cervical discharge.

Key Differentials — Same-Category Causes of Neonatal Sepsis

— IAP with ampicillin/penicillin may have selected for resistant E. coli, raising concern in some preterm cohorts.

— Viridans streptococci and enterococci — bacteremia/endocarditis sources; enterococci are intrinsically resistant to cephalosporins.

— Group A streptococcus (S. pyogenes) — puerperal sepsis ("childbed fever"); aggressive course, may cause toxic shock; penicillin + clindamycin for toxin suppression.

Even with adequate maternal IAP, neonatal early-onset sepsis can be caused by organisms other than GBS — recognizing the differential prevents undertreatment.

E. coli — now the leading cause of early-onset sepsis in preterm and very-low-birth-weight infants. Some strains are ampicillin-resistant; empiric coverage requires aminoglycoside.

Listeria monocytogenes — gram-positive rod; transplacental infection causing granulomatosis infantiseptica, sometimes with maternal flu-like illness and brown-stained amniotic fluid. Ampicillin remains first-line (penicillin G also active).

Other streptococci:

Staphylococcus aureus (including MRSA) — wound infections, late-onset neonatal disease, mastitis.

Haemophilus influenzae (non-typeable) — occasional neonatal sepsis; covered by ampicillin if susceptible.

Anaerobes (Bacteroides, Prevotella) — polymicrobial chorioamnionitis and postpartum endometritis; covered by clindamycin or metronidazole.

Key distinction: Ampicillin + gentamicin empirically covers GBS, Listeria, most E. coli, and enterococci — that's why it's the universal neonatal sepsis starter regimen rather than penicillin alone.

Board pearl: If maternal blood cultures grow gram-positive rods, think Listeria — ampicillin is first-line. Avoid cephalosporins; Listeria is intrinsically resistant to all cephalosporins (a classic Step 3 fact).

Step 3 management: Neonatal sepsis empiric regimen is ampicillin + gentamicin for early-onset; switch to vancomycin + cefotaxime (or gentamicin) for late-onset where Staph and gram-negatives dominate.

Always confirm pathogen identity before narrowing — empiric coverage saves lives, narrow therapy saves microbiomes.

Key Differentials — Other-Category Causes of Intrapartum/Postpartum Fever

— Epidural-associated fever — common, benign, gradual rise after epidural placement; no leukocytosis, fetal HR may be unaffected. Diagnosis of exclusion.

— Dehydration in prolonged labor — mild temperature elevation, responsive to fluids.

— Thyroid storm, malignant hyperthermia, transfusion reaction — context-driven.

— Drug fever — antibiotics themselves (especially β-lactams) can cause fever after several days.

— Pyelonephritis — flank pain, costovertebral angle tenderness, pyuria; E. coli most common. Treat with IV ceftriaxone; admit pregnant patients.

— Appendicitis — RLQ pain shifted upward in late pregnancy; surgical emergency. Fever may be modest.

— Influenza or COVID-19 — respiratory symptoms, seasonal context, lymphopenia.

— Pneumonia (community-acquired) — cough, hypoxia, infiltrate.

— Septic abortion (in earlier gestations) — retained products, fever, sepsis.

— Mastitis or breast abscess (postpartum) — focal breast erythema, S. aureus most common.

— Wound infection post-cesarean — erythema, induration, drainage at incision.

— Septic pelvic thrombophlebitis — persistent fever despite antibiotics, normal exam; diagnosis of exclusion confirmed by therapeutic anticoagulation response.

— Endometritis — uterine tenderness, foul lochia, fever 24+ hours postpartum.

Maternal intrapartum or postpartum fever is not always GBS or chorioamnionitis — broaden the differential:

Non-infectious causes:

Other infectious sources mimicking GBS-related sepsis:

Key distinction: Postpartum fever within the first 24 hours is often non-infectious or atelectasis-related; fever after 24 hours demands a focused infectious workup. Persistent fever despite appropriate antibiotics → think septic pelvic thrombophlebitis or retained products / abscess.

Board pearl: A pregnant patient with fever, flank pain, and pyuria has pyelonephritis until proven otherwise — admit, IV antibiotics, monitor for preterm labor and ARDS (pregnant patients are at higher risk for both complications).

Step 3 management: Always urinalysis + urine culture, CBC, blood cultures, lactate, and a focused exam (breasts, incision, fundus, lungs, CVA) for any postpartum fever > 38°C.

Secondary Prevention, Discharge, and Long-Term Plan

— No maternal antibiotic continuation required after delivery for uncomplicated IAP recipients.

— Document GBS status, IAP drug and timing, and neonatal disposition in the discharge summary — critical for future pregnancies.

— Counsel: next pregnancy will require re-screening at 36–37 weeks; do not assume positive or negative.

— Prior infant with invasive GBS disease → flag chart; all future pregnancies receive automatic IAP without screening.

— GBS bacteriuria during this pregnancy → does not automatically extend to future pregnancies (re-evaluate next time).

— No licensed maternal GBS vaccine yet, but investigational hexavalent conjugate vaccines are in late-phase trials — counsel patients about the possibility.

— Ensure other prenatal/postpartum vaccines (Tdap, influenza, COVID-19, RSV maternal vaccine at 32–36 weeks) are up to date — these protect the neonate against complementary pathogens.

— Watch for signs of late-onset GBS (7 days to 3 months): fever, poor feeding, lethargy, irritability, breathing difficulty — return immediately, do not wait for the pediatric appointment.

— Routine pediatric follow-up at 2–3 days, then 2 weeks, then standard well-baby schedule.

— Encouraged. GBS in breast milk is rare; not a reason to stop breastfeeding even if mother was colonized.

— If maternal mastitis develops, treat with dicloxacillin or cephalexin (S. aureus coverage), continue nursing.

Postpartum and discharge planning after a GBS-positive pregnancy:

Patients with an automatic IAP indication going forward:

Maternal vaccination opportunity:

Neonatal discharge instructions for parents:

Breastfeeding:

Step 3 management: On the postpartum check at 6 weeks, document GBS status from the pregnancy in the long-term record; counsel about implications for future pregnancies and contraception planning.

Board pearl: IAP prevents early-onset GBS disease only. Parents must understand that late-onset disease can still occur — this counseling point appears in vignettes asking about appropriate discharge teaching.

Follow-Up, Monitoring, and Counseling

— Maternal vitals per routine postpartum protocol; specifically watch for fever, uterine tenderness, foul lochia (endometritis), or wound issues (cesarean).

— Neonatal observation: at minimum 36–48 hours for any infant with maternal GBS positivity or risk factors, per AAP. Vital signs q4h initially.

— If IAP was inadequate (< 4 h of penicillin/ampicillin/cefazolin), neonatal evaluation is intensified per the EOS risk calculator — often CBC at 6–12 h, blood culture, possibly empiric antibiotics if symptomatic.

— 2 weeks for cesarean wound check or by clinical need.

— 3–6 weeks comprehensive postpartum visit — review delivery course, mood (PHQ-9 for postpartum depression), contraception, breastfeeding, and document GBS history for the lifetime record.

— GBS is not a sexually transmitted infection and does not require partner treatment — recurring misconception.

— Carriage may come and go; future pregnancies require re-screening.

— IAP does not affect future fertility, lactation, or long-term maternal microbiome significantly (single-day exposure to narrow-spectrum penicillin).

— Reassure that GBS positivity in pregnancy is common (1 in 4 pregnancies) and adequately managed with IAP.

— IAP administration rates are tracked as perinatal quality indicators.

— Document time-to-first-dose; centers aim for IAP initiation within 1 hour of meeting indication.

Postpartum monitoring after GBS-positive delivery:

Maternal follow-up cadence:

Counseling content for the patient:

Quality measures and value-based care:

CCS pearl: Schedule the postpartum visit at 3–6 weeks, order contraception counseling, postpartum depression screening, and confirm immunizations updated (Tdap if not given, MMR/varicella if non-immune, postpartum).

Board pearl: A patient asking "Will I be GBS-positive again next time?" → answer: carriage is transient and intermittent; we will rescreen each pregnancy. This is a frequent counseling stem.

Ethical, Legal, and Patient Safety Considerations

— Patients can decline IAP. Document refusal, alternatives discussed, and neonatal risks (EOGBS mortality 2–3% term, 20–30% preterm; meningitis sequelae).

— Use shared decision-making language; respect autonomy even when refusal increases neonatal risk. Involve ethics consultation if conflict persists.

— In emancipated minors and adolescent obstetric patients, the pregnant patient consents for herself and her neonate per most state laws — confirm local statute.

— Antenatal GBS result must reach L&D — system failures include lost lab results, transfer between facilities, late prenatal entry. Build a standardized handoff that includes GBS status, allergy phenotype, and prior infant outcomes.

— Time of last antibiotic dose must transfer to the neonatal team in the delivery note; missing this triggers unnecessary neonatal interventions.

— Mislabeled penicillin allergies lead to vancomycin overuse, longer length of stay, higher cost, and inadequate IAP per current definitions.

— Penicillin allergy de-labeling antenatally is a patient-safety intervention; refer in the 2nd trimester.

— Invasive GBS disease in a neonate is reportable in many states via the Active Bacterial Core surveillance (ABCs) network.

— Maternal sepsis cases are reviewed by hospital morbidity committees and state perinatal quality collaboratives.

— When a parent refuses neonatal sepsis workup despite indicated risk, document discussion, engage social work and ethics, and consider child protective services consultation if neonatal safety is at imminent risk.

Informed consent for IAP:

Transition-of-care vulnerabilities (Step 3 favorite):

Allergy documentation safety:

Mandatory reporting and public health:

Refusal of neonatal evaluation:

Step 3 management: A pregnant patient with documented penicillin "allergy" of unknown reaction presenting in labor → the safest action is cefazolin (low cross-reactivity, adequate coverage) only if the history excludes anaphylaxis or SJS; otherwise vancomycin. Clarifying the allergy is itself a safety intervention.

Board pearl: Refusing IAP does not constitute fetal/neonatal abuse; it is a competent autonomous decision when properly informed.

High-Yield Associations and Rapid-Fire Clinical Facts

— Screen 36 0/7 to 37 6/7 weeks — result valid 5 weeks.

— Specimen: lower vagina + rectum, same swab, no speculum.

— First-line: Penicillin G 5 MU IV load, then 2.5–3 MU q4h until delivery.

— Cefazolin for low-risk allergy; clindamycin if high-risk allergy AND isolate susceptible AND D-test negative; vancomycin otherwise.

— Adequate IAP = ≥4 hours of penicillin/ampicillin/cefazolin before delivery.

— Clindamycin and vancomycin do not count toward adequate IAP for neonatal stratification.

— Automatic IAP without screen: GBS bacteriuria this pregnancy, prior infant with invasive GBS disease.

— No IAP needed: scheduled cesarean before labor with intact membranes (regardless of GBS status).

— GBS bacteriuria ≥10⁵ CFU/mL → treat now AND give IAP at delivery.

— Vancomycin dosing: 20 mg/kg IV q8h, max 2 g/dose (updated 2019).

— Erythromycin is no longer recommended for GBS IAP.

— Listeria is intrinsically resistant to cephalosporins — Step 3 trap.

— Group A strep puerperal sepsis treated with penicillin + clindamycin for toxin suppression.

— Late-onset GBS (7–89 days) is NOT prevented by IAP — parental counseling required.

— Triple I replaces "chorioamnionitis" in modern ACOG terminology.

— Postpartum endometritis treatment: clindamycin + gentamicin, no oral step-down for uncomplicated cases.

— PPROM latency regimen: ampicillin + azithromycin + amoxicillin for 7 days.

— Pre-cesarean cefazolin covers GBS; add azithromycin for unscheduled cesarean.

— GBS is NOT an STI — partners are not treated.

— Re-screen every pregnancy; do not assume status from prior pregnancies.

Rapid-fire pearls Step 3 returns to repeatedly:

Board pearl: If the vignette specifies "penicillin allergy with hives and throat swelling" → that is anaphylaxis-class → vancomycin (skip cefazolin and clindamycin in most question writers' logic).

Board Question Stem Patterns

— Answer: Perform rectovaginal GBS culture this pregnancy. Prior positive does not mandate IAP.

— Answer: Vancomycin 20 mg/kg IV q8h.

— Answer: Start IAP empirically (preterm + unknown status). Penicillin G is first-line.

— Answer: Standard pre-incision cefazolin for surgical prophylaxis. No separate IAP needed.

— Answer: Inadequate IAP (< 4 h). Neonatal observation per AAP algorithm; evaluate per EOS calculator.

— Answer: Treat with amoxicillin now AND give IAP at delivery. Skip the 36-week screen — already an automatic IAP candidate.

— Answer: Automatic IAP in every subsequent pregnancy; no screening required.

— Answer: Triple I → broaden to ampicillin + gentamicin, expedite delivery, notify neonatology.

— Answer: Endometritis → clindamycin + gentamicin IV until afebrile 24–48 h.

Common Step 3 vignette structures and the expected answer:

Stem 1: "G2P1 at 36 weeks for routine visit. Prior pregnancy was GBS positive, neonate did well. What now?"

Stem 2: "GBS positive at 37 weeks, presents in active labor with anaphylactic penicillin allergy. Cultures show clindamycin-resistant GBS."

Stem 3: "GBS unknown, presents at 35 weeks with ROM, labor pattern."

Stem 4: "Scheduled cesarean at 39 weeks, GBS positive on screen, no labor, intact membranes."

Stem 5: "GBS-positive patient receives one dose of penicillin G two hours before vaginal delivery. Neonate vigorous at birth."

Stem 6: "Pregnant patient at 14 weeks with asymptomatic urine culture growing GBS 100,000 CFU/mL."

Stem 7: "G3P2, prior infant had GBS meningitis at day 3 of life."

Stem 8: "GBS-positive patient in labor develops fever 38.5°C, fetal tachycardia 170, foul-smelling fluid."

Stem 9: "Postpartum day 2, GBS-positive vaginal delivery, fever 38.7°C, uterine tenderness."

Board pearl: Step 3 loves the "adequate vs inadequate IAP" distinction and the prior-pregnancy-GBS does NOT mandate current IAP trap — drill both.

One-Line Recap

Universal rectovaginal screening at 36 0/7–37 6/7 weeks, intrapartum penicillin G ≥4 hours before delivery for any positive screen, GBS bacteriuria, or prior invasive neonatal disease, with cefazolin/clindamycin/vancomycin reserved by allergy phenotype and isolate susceptibility — that is the entirety of GBS prevention.

Screen: rectovaginal swab, 36 0/7–37 6/7 weeks, valid 5 weeks; automatic IAP without screening if GBS bacteriuria this pregnancy or prior infant with invasive GBS disease.

Treat in labor: Penicillin G 5 MU IV load → 2.5–3 MU q4h until delivery; cefazolin for low-risk penicillin allergy; clindamycin only if susceptible and D-test negative; vancomycin 20 mg/kg q8h for anaphylaxis-class allergy with resistance/unknown susceptibility.

Adequacy: ≥4 hours of penicillin/ampicillin/cefazolin before delivery defines "adequate"; clindamycin and vancomycin do not count for neonatal risk stratification.

Exceptions: Scheduled cesarean with intact membranes and no labor → no IAP regardless of GBS status (pre-incision cefazolin alone suffices); prior GBS-positive pregnancy without neonatal disease → re-screen, don't assume.

Counseling and continuity: GBS is not an STI, partners are not treated, screening is re-done every pregnancy, and IAP prevents early-onset but not late-onset disease — discharge teaching about neonatal fever, feeding, and lethargy in the first 3 months matters as much as the antibiotic itself.

Step 3 management: Document GBS status, allergy phenotype, time of first IAP dose, and adequacy at every handoff — these four data points drive neonatal care decisions long after the patient leaves L&D.